A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

NCT07464912 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

508

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG: TDI01

Sponsor

Beijing Tide Pharmaceutical Co., Ltd

Collaborators

[object Object]